Prognostic Value of EndoPredict in Patients With HR+/HER2− Primary Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
ESMO Open
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trial
ESMO Open 2024 Apr 30;9(5)103443, F Penault-Llorca, F Dalenc, S Chabaud, P Cottu, D Allouache, D Cameron, J Grenier, L Venat Bouvet, A Jegannathen, M Campone, M Debled, AC Hardy-Bessard, S Giacchetti, P Barthelemy, L Kaluzinski, A Mailliez, MA Mouret-Reynier, E Legouffe, A Cayre, M Martinez, C Delbaldo, D Mollon-Grange, EJ Macaskill, M Sephton, L Stefani, B Belgadi, M Winter, H Orfeuvre, M Lacroix-Triki, H Bonnefoi, J Bliss, JL Canon, J Lemonnier, F Andre, T BachelotFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.